SHARE is an easy-to-search, real-time repository of HIV-related systematic reviews. Whether you’re a researcher, community member, healthcare provider or policymaker, SHARE provides a ‘one-stop shop’ for HIV-related information that has been published through a systematic review.

OBJECTIVE: To contrast available once-daily antiretroviral agents and combinations of these agents from a clinical pharmacologic viewpoint. DATA SOURCES: Data were extracted from publications and major HIV conference proceedings cited...

Context: The minimum standard of care required for participants in clinical trials conducted in resource-poor settings is a matter of controversy; international documents offer contradictory guidance. Objective: To determine whether...

This paper reviews the pharmacoeconomic aspects of antenatal testing for HIV. HIV is a retrovirus which is transmitted among humans through sexual contact, infected blood or blood products (needle sharing...

BACKGROUND: Sexually transmitted infections (STI) are common in developing countries. The World Health Organisation (WHO) estimates that in 1999, 340 million new cases of syphilis, gonorrhoea, chlamydial infection and trichomoniasis...

Purpose: To present a metasynthesis of qualitative findings on stigma in HIV-positive women. Method: Metasummary and metasynthesis techniques were used to integrate findings on stigma in 93 reports of qualitative...

PURPOSE: To assess the efficacy of recombinant human growth hormone (rhGH), testosterone, and anabolic steroids in the treatment of HIV wasting. METHODS: A systematic review and meta-analysis of studies published...

PURPOSE: A successful prophylactic HIV vaccine will probably require neutralizing antibodies and vigorous CTL (CD8+ T-cytotoxic lymphocyte) responses. Canarypox vector-based HIV vaccines (ALVAC-HIV) have been gaining momentum as promising HIV...

PURPOSE: The pharmacology, pharmacokinetics, and clinical trials of and drug interactions and formulary considerations associated with atazanavir, the newest protease inhibitor (PI) to treat human immunodeficiency virus (HIV) infection, are...

We examined the peer-reviewed literature on the burden of bacterial pneumonia and the effectiveness of interventions for its prevention among HIV-infected adults in developed and developing countries. Bacterial pneumonia rates...

Fosamprenavir (GW433908, Lexiva, Telzir) is an oral prodrug of the protease inhibitor (PI) amprenavir, with a reduced daily pill burden. Fosamprenavir, in combination with other antiretroviral agents, is indicated for...

The enrolling of adequate participants into HIV experimental drug trials presents an important challenge. We systematically reviewed the literature to identify barriers and concerns amongst HIV patients to participation in...

This systematic review summarises the evidence for treatment efficacy and tolerability of highly active antiretroviral therapies containing two nucleoside reverse transcriptase inhibitors (NRTI) with a protease inhibitor (PI), compared with...